Cyclacel Pharmaceuticals, Inc. (CYCC) stock price away from 20 day simple moving average slumped at -20.60% while its distance from 50 day simple moving average declined -29.46% along with -33.30% below away from two hundred simple moving averages. On technical aspect, moving averages may help to distinguish path of dispositions, and they may also be used to set degrees of support and resistance. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
The Stock has Weekly volatility of 9.29% and monthly volatility of 7.41%. Tracking most recent quarter period, Price to book (P/B) ration is at 1.03 and Price to cash per share ration is at 1.08. Beta value of the stock is marked at 3.52. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security’s price will be more volatile than the market. The company has a Return on Assets (ROA) of -53.70%. Presently, it has a Return on Equity (ROE) of -73.50% and Return on Investment (ROI) of -85.10%. Relative strength index (RSI-14) for Cyclacel Pharmaceuticals, Inc. (CYCC) is at 24.06. Average true range (ATR-14) of the company is at 0.29.
Cyclacel Pharmaceuticals, Inc. (CYCC) stock price tumbled -11.97% to finalize at $3.09 throughout previous buying and selling session. A total of 0.98 million shares exchanged at hands and its average trading volume is standing at 0.08 million shares. Important factors to focus when evaluating a stock’s present and future value are the 52 week price high and low levels. Shares of Cyclacel Pharmaceuticals, Inc. (CYCC) are trading -71.65% downward from the 52-week high mark and 1.31% above from the fifty two-week low mark.
Taking a glance at past performance, we will examine different up or down moving trends about CYCC. The stock dropped -10.43% beyond one week and declined -24.26% during previous one month session. The stock went down -46.17% at some stage in past quarter. Inside the closing six months period the stock’s performance declined -43.09% while overall yearly performance lost -39.05%. The Company’s year to date (YTD) performance is now negative at -41.59%.